Wondering if anyone out there is taking this as a supplement. Either as the Life Extension brand 5-LOXIN or through a Boswellia Supplement. Thanks!
5-LOX Inhibitor: Wondering if anyone... - Advanced Prostate...
5-LOX Inhibitor
Thanks Nals!
My husband takes a boswellia supplement too. Do you folks have any suggestions as to dosing ?
thanks!
Softwaremom
Hi Brian,
See my post of 2 years ago:
"Foods/Supplements-Vitamins: Boswellic Acid".
& here is the 5-LOXIN site:
5-LOXIN inhibits 5-LOX (5-lipoxygenase aka arachidonate 5-lipoxygenase) which is a major instigator of inflammation in PCa.
When Dr. Myers was at UVA, he co-authored a paper (with Ghosh) on 5-LOX:
[1] (2002) "Molecular mechanisms of prostate cancer cell death triggered by inhibition of arachidonate 5-lipoxygenase ..."
[2] (2015) Ghosh & others: "we observed that inhibition of 5-Lox severely down-regulates the expression of c-Myc oncogene in prostate cancer cells. Moreover, inhibition of 5-Lox dramatically decreases the protein level, nuclear accumulation, DNA binding, and transcriptional activities of c-Myc."
I take 2 caps/day.
5-LOXIN is the same regardless of brand, so shop by price.
Or go for any boswellia product that lists the AKBA content.
-Patrick
[1] link.springer.com/chapter/1...
[2] ncbi.nlm.nih.gov/pubmed/255...
Patrick,
how many mgs are in each pill you take of 5-lox ?
125 mg - 30% AKBA
I read this today, then came to search on healthunlocked, sound like 250mg a day is a good amount or maybe 150 x 2 (1 in the morning, 1 at night) : Vitacost Synergy 5-Loxin®-AKBA Boswellia Extract -- 150 mg per serving - 120 Capsules?
Conclusion: 5-Loxin reduces pain and improves physical functioning significantly in OA patients; and it is safe for human consumption. 5-Loxin may exert its beneficial effects by controlling inflammatory responses through reducing proinflammatory modulators, and it may improve joint health by reducing the enzymatic degradation of cartilage in OA patients.
A double blind, randomized, placebo controlled study of the efficacy and safety of 5-Loxin for treatment of osteoarthritis of the knee
Krishanu Sengupta 1, Krishnaraju V Alluri, Andey Rama Satish, Simanchala Mishra, Trimurtulu Golakoti, Kadainti Vs Sarma, Dipak Dey, Siba P Raychaudhuri
Affiliations expand
PMID: 18667054 PMCID: PMC2575633 DOI: 10.1186/ar2461
Free PMC article
Abstract
Introduction: 5-Loxin is a novel Boswellia serrata extract enriched with 30% 3-O-acetyl-11-keto-beta-boswellic acid (AKBA), which exhibits potential anti-inflammatory properties by inhibiting the 5-lipoxygenase enzyme. A 90-day, double-blind, randomized, placebo-controlled study was conducted to evaluate the efficacy and safety of 5-Loxin in the treatment of osteoarthritis (OA) of the knee.
Methods: Seventy-five OA patients were included in the study. The patients received either 100 mg (n = 25) or 250 mg (n = 25) of 5-Loxin daily or a placebo (n = 25) for 90 days. Each patient was evaluated for pain and physical functions by using the standard tools (visual analog scale, Lequesne's Functional Index, and Western Ontario and McMaster Universities Osteoarthritis Index) at the baseline (day 0), and at days 7, 30, 60 and 90. Additionally, the cartilage degrading enzyme matrix metalloproteinase-3 was also evaluated in synovial fluid from OA patients. Measurement of a battery of biochemical parameters in serum and haematological parameters, and urine analysis were performed to evaluate the safety of 5-Loxin in OA patients.
Results: Seventy patients completed the study. At the end of the study, both doses of 5-Loxin conferred clinically and statistically significant improvements in pain scores and physical function scores in OA patients. Interestingly, significant improvements in pain score and functional ability were recorded in the treatment group supplemented with 250 mg 5-Loxin as early as 7 days after the start of treatment. Corroborating the improvements in pain scores in treatment groups, we also noted significant reduction in synovial fluid matrix metalloproteinase-3. In comparison with placebo, the safety parameters were almost unchanged in the treatment groups.
Conclusion: 5-Loxin reduces pain and improves physical functioning significantly in OA patients; and it is safe for human consumption. 5-Loxin may exert its beneficial effects by controlling inflammatory responses through reducing proinflammatory modulators, and it may improve joint health by reducing the enzymatic degradation of cartilage in OA patients.
Hmmmm nothing beats Bagels and LOXin.
Good Luck and Good Health.
j-o-h-n 04/22/2018 12:39 PM EDT
I take 5-Loxin also. Buy from VitaCost. I wanted to mention another supplement that inhibits 5-lipoxygenase is Milk Thistle. See article titled: Evaluation of The Cinical Use of Silymarin in Knee Osteoarthritis: Application of the Dual Inhibitory Concept of Cyclooxygenase and 5-Lipoxygenase
Link: researchgate.net/publicatio...
-Dave
Nal, I've been taking 2 pills a day (1 morning, 1 night) from life extension for about 18 months now. Thinking about switching to Vitacost Synergy 5-Loxin®-AKBA Boswellia Extract -- 150 mg per serving - 120 Capsules, after reading these study results below of 250mg per day. Maybe 300 (with vitacost) per day would be better than 200 (with L.Extension)
How is your friend from Bayer doing? That's amazing that he's doing that well on supplements only. Did he stop ADT after the 3 years on it?
Conclusion: 5-Loxin reduces pain and improves physical functioning significantly in OA patients; and it is safe for human consumption. 5-Loxin may exert its beneficial effects by controlling inflammatory responses through reducing proinflammatory modulators, and it may improve joint health by reducing the enzymatic degradation of cartilage in OA patients.
A double blind, randomized, placebo controlled study of the efficacy and safety of 5-Loxin for treatment of osteoarthritis of the knee
Krishanu Sengupta 1, Krishnaraju V Alluri, Andey Rama Satish, Simanchala Mishra, Trimurtulu Golakoti, Kadainti Vs Sarma, Dipak Dey, Siba P Raychaudhuri
Affiliations expand
PMID: 18667054 PMCID: PMC2575633 DOI: 10.1186/ar2461
Free PMC article
Abstract